Literature DB >> 23333363

Arrhythmia and exercise intolerance in Fontan patients: current status and future burden.

L Idorn1, K Juul, A S Jensen, B Hanel, K G Nielsen, H Andersen, J I Reimers, K E Sørensen, L Søndergaard.   

Abstract

BACKGROUND: Long-term survival after the Fontan procedure shows excellent results but is associated with a persistent risk of arrhythmias and exercise intolerance. We aimed to analyze the current burden of clinically relevant arrhythmia and severe exercise intolerance in Danish Fontan patients and furthermore, to estimate the future burden from analysis of mortality and the current burden related to age.
METHODS: All Danish citizens with Fontan completion from 1981 to 2009 were identified (n=235). Surviving patients performed exercise test, Holter monitoring, echocardiography, pulmonary function test, and blood sampling and medical history was retrieved from medical records.
RESULTS: Twenty-six (11%) patients died or had heart transplantation (HTx) after a mean (± SD) post-Fontan follow-up of 8.3 ± 5.7 years. Excluding perioperative deaths (n=8), a linear probability of HTx-free survival was observed and estimated to 99.1% per year. Prevalence of clinically relevant arrhythmia and severe exercise intolerance increased significantly with age and was found in 32% and 85% of patients ≥ 20 years, respectively. Thus, from survival data and logistic regression models the future prevalence of patients, clinically relevant arrhythmia and severe exercise intolerance were estimated, revealing a considerable augmentation. Furthermore, resting and maximum cardiac index, resting stroke volume index and pulmonary diffusing capacity decreased significantly with age while diastolic and systolic ventricular function was unchanged.
CONCLUSIONS: The prevalence of clinically relevant arrhythmia and severe exercise intolerance increased significantly with age in Danish Fontan patients. The future Fontan burden was estimated showing an increase in the prevalence of older patients, clinically relevant arrhythmia, and severe exercise intolerance.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Arrhythmia; Exercise capacity; Fontan procedure; Prognosis

Mesh:

Year:  2013        PMID: 23333363     DOI: 10.1016/j.ijcard.2012.12.055

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Clinical Profile and Quality of Life of Adult Patients After the Fontan Procedure.

Authors:  Giulia Bordin; Massimo Antonio Padalino; Sonja Perentaler; Biagio Castaldi; Nicola Maschietto; Pierantonio Michieli; Roberto Crepaz; Anna Chiara Frigo; Vladimiro Lorenzo Vida; Ornella Milanesi
Journal:  Pediatr Cardiol       Date:  2015-04-02       Impact factor: 1.655

Review 2.  Current Therapy for Hypoplastic Left Heart Syndrome and Related Single Ventricle Lesions.

Authors:  Richard G Ohye; Dietmar Schranz; Yves D'Udekem
Journal:  Circulation       Date:  2016-10-25       Impact factor: 29.690

3.  Long-Term Effects of Percutaneous Fenestration Following the Fontan Procedure in Adult Patients with Congenital Univentricular Heart.

Authors:  Monika Smaś-Suska; Beata Róg; Piotr Weryński; Wojciech Płazak; Monika Komar; Maria Olszowska; Piotr Podolec; Lidia Tomkiewicz-Pająk
Journal:  Med Sci Monit       Date:  2018-05-26

4.  Prognostic power of cardiopulmonary exercise testing in Fontan patients: a systematic review.

Authors:  Sebastian Udholm; Nael Aldweib; Vibeke Elisabeth Hjortdal; Gruschen R Veldtman
Journal:  Open Heart       Date:  2018-07-03

5.  Prevalence of Arrhythmia in Adults after Fontan Operation.

Authors:  Magdalena Okólska; Grzegorz Karkowski; Marcin Kuniewicz; Jacek Bednarek; Jacek Pająk; Beata Róg; Jacek Łach; Jacek Legutko; Lidia Tomkiewicz-Pająk
Journal:  J Clin Med       Date:  2022-04-01       Impact factor: 4.241

Review 6.  Factors influencing adaptation and performance at physical exercise in complex congenital heart diseases after surgical repair.

Authors:  P P Bassareo; L Saba; P Solla; C Barbanti; A R Marras; G Mercuro
Journal:  Biomed Res Int       Date:  2014-04-15       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.